Evidence map›Paper›PMID 29308211›Full record

ArticleOxford medical case reports2017

Elevated homocysteine and

Simon Vann Jones, Subimal Banerjee, A David Smith, Helga Refsum, Belinda Lennox

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford medical case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Simon Vann JonesDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.ORCID 0000-0003-4721-6282
Subimal BanerjeeWarneford Hospital, Oxford Health NHS Foundation Trust, Oxford OX3 7JX, UK.
A David SmithDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Helga RefsumInstitute of Basic Medical Sciences, University of Oslo, Postboks 1046, Blindern, 0317 Oslo, Norway.
Belinda LennoxDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
University of Oxford · GBOxford Health NHS Foundation Trust · GBUniversity of Oslo · NO

Funding

Medical Research Council MR/J012939/1Medical Research Council MR/N019067/1
6 · The paper itself

Abstract

A 19-year-old male with 22q11.2 deletion syndrome presented with a 4-year history of cognitive decline and symptoms suggestive of atypical psychosis. Potential for elevated homocysteine and NMDA-receptor antibodies in the pathogenesis of his symptoms was investigated. He had elevated blood homocysteine level (18.7 μmol/l), low-normal vitamin B12 and folate levels and was positive for NMDA-receptor antibodies. Treatment with daily folinic acid (0.8 mg) and vitamin B12 (1 mg) led to dramatic improvement in his cognitive and behavioural presentation. Subsequent plasma exchange resulted in a further, significant clinical improvement. Homocysteine levels and NMDA-R antibodies should be investigated as potential causes of behavioural and cognitive symptoms in patients with 22q11.2 deletion syndrome.

Identifiers

PMID29308211
PMCPMC5751082
OpenAlexW2780012144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.